Keros Therapeutics (NASDAQ:KROS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage currently has a $49.00 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 6.54% from the stock’s current price.
According to Zacks, “Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company’s product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA. “
Separately, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, March 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and a consensus price target of $77.25.
Keros Therapeutics (NASDAQ:KROS – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.15). During the same period last year, the company earned ($0.68) earnings per share. On average, equities analysts forecast that Keros Therapeutics will post -4.41 EPS for the current fiscal year.
In other Keros Therapeutics news, COO Christopher Rovaldi sold 1,728 shares of the stock in a transaction dated Wednesday, April 6th. The stock was sold at an average price of $65.00, for a total value of $112,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jennifer Lachey sold 7,950 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $60.00, for a total value of $477,000.00. Following the completion of the sale, the insider now owns 85,700 shares of the company’s stock, valued at $5,142,000. The disclosure for this sale can be found here. Insiders have sold a total of 20,278 shares of company stock valued at $1,201,417 over the last 90 days. 36.10% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC purchased a new stake in Keros Therapeutics in the fourth quarter valued at about $40,000. Royal Bank of Canada raised its stake in shares of Keros Therapeutics by 22.6% in the third quarter. Royal Bank of Canada now owns 1,433 shares of the company’s stock worth $57,000 after purchasing an additional 264 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Keros Therapeutics by 548.8% in the third quarter. Macquarie Group Ltd. now owns 1,622 shares of the company’s stock worth $64,000 after purchasing an additional 1,372 shares during the last quarter. Ensign Peak Advisors Inc purchased a new position in shares of Keros Therapeutics in the fourth quarter worth about $139,000. Finally, SG Americas Securities LLC raised its stake in shares of Keros Therapeutics by 9.0% in the first quarter. SG Americas Securities LLC now owns 2,944 shares of the company’s stock worth $160,000 after purchasing an additional 243 shares during the last quarter. Institutional investors own 74.82% of the company’s stock.
Keros Therapeutics Company Profile (Get Rating)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.
- Get a free copy of the StockNews.com research report on Keros Therapeutics (KROS)
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.